Genzyme Recognizes International Rare Disease Day with the launch of a new website and the Third Annual Patient Advocacy

Genzyme Recognizes International Rare Disease Day with the launch of a new 
website and the Third Annual Patient Advocacy Leadership Awards 
TORONTO, Feb. 27, 2013 /CNW/ - Genzyme, a Sanofi company, today announced its 
support of International Rare Disease Day with a series of initiatives meant 
to call attention to rare diseases as an important public health issue and to 
improve rare disease education, research, and treatment. Observed annually on 
the last day of February, Rare Disease Day is an international awareness 
campaign organized by the patient organization EURORDIS and supported by 
hundreds of other patient organizations around the world. 
February 28, 2013 marks the sixth International Rare Disease Day. This year's 
theme, "Rare Disorders without Borders," emphasizes that international 
cooperation is essential for fighting diseases that affect only a few people 
in each country and for which expertise is scarce and scattered. In 
celebration of this theme, Genzyme is pleased to launch a new website 
highlighting collaborative activities taking place globally to recognize Rare 
Disease Day: 
Genzyme sites around the world are partnering with local patient organizations 
on a variety of Rare Disease Day activities meant to educate policymakers, 
medical professionals, patients and caregivers, and the general public and 
empower them to advocate for those affected by rare diseases. A Canadian 
initiative, among many other global projects, includes: 

    --  Launch of "Facing Fabry Together," a film that tells the
        stories of families from France, Germany, Brazil, and Canada
        living with Fabry disease. The featured Canadian family live on
        the eastern edge of Nova Scotia. The mother's father and one of
        her two sons were diagnosed with Fabry disease in 2000. At the
        time, the mother was identified only as a carrier. In 2004, her
        increasing symptoms led to genetic testing, revealing what she
        and her husband had suspected. She was more than "just a
        carrier." Visit
        to watch the film online.

Annual Patient Advocacy Leadership (PAL) Awards 
Additionally, Genzyme is pleased to announce the launch of the third annual 
Patient Advocacy Leadership Awards, a global grant program supporting 
non-profit patient organizations that work on behalf of individuals living 
with lysosomal storage disorders (LSDs), a group of rare, inherited disorders 
that cause progressive and debilitating health problems. Grants are awarded 
through a competitive process to organizations that seek funding for 
innovative programs and projects that improve disease awareness, patient care, 
support, and education. In 2012, more than 50 patient organizations 
representing 27 countries submitted proposals, and nine winners chosen by an 
external review committee received a total of $100,000 from Genzyme.

Saluting Canada's New Orphan Drug Policy
Genzyme commends the Federal Government for implementing the new Orphan Drug 
Policy, the first ever Canadian framework to increase access to new treatments 
and information for rare diseases. The Canadian Organization for Rare 
Disorders (CORD) needs to also be applauded for their persistency and tireless 
efforts in helping the Federal Government build this remarkable infrastructure 
that will benefit all Canadians who live with rare diseases. This highly 
anticipated regulatory framework is a major step forward, opening the way for 
research and development of new drugs for "orphan" indications and improving 
access to existing therapies.

The Orphan Drug Policy also opens the way for a Canadian Plan for Rare 
Diseases, including guidelines for newborn screening, diagnosis, and the 
creation of Centres of Reference.

"Canada's new orphan drug policy is a long overdue public commitment and 
Genzyme Canada commends the Federal Government for moving the rare diseases 
agenda forward to ensure our country is aligned with other global 
jurisdictions," says Peter Brenders, General Manager, Genzyme Canada. "And 
CORD is to be congratulated for its tireless dedication and determination in 
advocating for rare diseases over the years and pushing to make this policy a 
reality for this vulnerable and often forgotten patient population."

More About Genzyme Patient Advocacy Leadership (PAL) Awards
Organizations may apply for a Genzyme PAL Award for programs that support 
lysosomal storage disorder awareness, advocacy on behalf of patient 
communities, patient education, patient care, support and communication 
networks. This grant program is supplemental to Genzyme's existing grants 
program and will not replace annual local support for advocacy groups. 
Proposals will be reviewed by an external review committee. Applications must 
be received by June 7, 2013 and the award recipients will be announced by 
September 30, 2013. For more information on the Genzyme PAL Awards program, or 
to apply for a grant, please visit

About Genzyme, a Sanofi Company 
Genzyme has pioneered the development and delivery of transformative therapies 
for patients affected by rare and debilitating diseases for over 30 years. We 
accomplish our goals through world-class research and with the compassion and 
commitment of our employees. With a focus on rare diseases and multiple 
sclerosis, we are dedicated to making a positive impact on the lives of the 
patients and families we serve. That goal guides and inspires us every day. 
Genzyme's portfolio of transformative therapies, which are marketed in 
countries around the world, represents groundbreaking and life-saving advances 
in medicine. As a Sanofi company, Genzyme benefits from the reach and 
resources of one of the world's largest pharmaceutical companies, with a 
shared commitment to improving the lives of patients. Learn more at

Genzyme(®) is a registered trademark of Genzyme Corporation. All rights 

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and 
distributes therapeutic solutions focused on patients' needs. Sanofi has core 
strengths in the field of healthcare with seven growth platforms: diabetes 
solutions, human vaccines, innovative drugs, consumer healthcare, emerging 
markets, animal health and the new Genzyme. Sanofi is listed in Paris 
(EURONEXT: SAN) and in New York (NYSE: SNY).

Media Contacts: Noëlle-Dominique Willems (905) 267-3176

Joanne Koskie (647) 259-3297

SOURCE: Genzyme

To view this news release in HTML formatting, please use the following URL:

CO: Genzyme
ST: Ontario

-0- Feb/27/2013 17:41 GMT